New HART CEO: 'I want to regenerate the esophagus and our stock price'

But tomorrow morning, HART (Nasdaq: HART) plans to announce that it is expanding its regenerated trachea technology into two new organs â€” the bronchus and esophagus. In an exclusive interview Wednesday, McGrorry said that initial studies with the updated organ regeneration technology have shown incredible results.
http://www.bizjournals.com/boston/blog/health-care/2015/11/newhart-ceo-i-want-to-regenerate-the-esophagus-and.html

AUDIENCES

Caregivers
Friends and Family
General Public
Medical Profession
Patients
Survivors

SUBJECTS

Post Surgical

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2025 Esophageal Cancer Education Foundation- by domino